Clinical trial · Observational
Concurrent Chemo-Radiotherapy for Limited Disease Small Cell Lung Cancer (LD-SCLC) on Basis of FDG-PET-Scans
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our group has shown that the omission of elective nodal irradiation on the basis of CT scans in patients with LD-SCLC lead to a higher than expected isolated nodal recurrence in the ipsilateral supraclavicular area. We have previously also shown that selective mediastinal nodal radiation on basis of FDG-PET scans in NSCLC is safe and reduces the radiation fields and hence toxicity. As the accuracy of FDG-PET scans is also in SCLC higher than CT, we will investigate the safety of selective nodal irradiation in LD-SCLC patients treated with concurrent chemo-radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small Cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- Inclusion criteria * Histological or cytological proven SCLC * UICC stage I-III, "limited disease" * Performance status 0-2 * FeV1 and DLCO at least 30% of age-predicted value Exclusion criteria: * Not SCLC or mixed SCLC and other histologies (e.g. non-small cell carcinoma) * stage IV * performance status 3 or more * FeV 1 or DLCO\< 30% of the age-predicted value
Primary outcomes (1)
- measure
- isolated Nodal Recurrences
- timeFrame
- 18 months post-treatment
Secondary outcomes (5)
- measure
- overall survival
- timeFrame
- 18 months post-treatment
- measure
- progression-free interval
- timeFrame
- 18 months post-treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological proven SCLC * UICC stage I-III, "limited disease" * Performance status 0-2 * FeV 1 and DLCO at least 30% of the age-predicted value Exclusion Criteria: * Not SCLC or mixed SCLC and other histologies (e.g. non-small cell lung carcinoma) * UICC stage IV * Performance status 3 or more * FeV 1 and DLCO \< 30% of the age-predicted value
References
Publications (0)
Data not yet available